October 12, 2015 08:55 ET
OCEANSIDE, CA–(Marketwired – Oct 12, 2015) – Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today that Harry M. Lander, Ph.D. has been appointed to our Scientific Advisory Board.
Dr. Lander was the Assistant Provost of Weill Cornell Medical College in New York City where, similarly, he oversaw the business of science from 2003 to 2013. From 1995-1999, Dr. Lander was an Assistant Professor of Biochemistry at Cornell University Medical College. His National Institutes of Health-funded laboratory studied the role of reactive nitrogen on the activation of the Ras superfamily of proteins and its role in carcinogenesis. He also served on the editorial board of Antioxidants and Redox Signaling and as a reviewer for a National Institutes of Health Study Section — Special Emphasis Panel.
“We are so very thankful to welcome Dr. Lander to our Scientific Advisory Board along with Dr. Santosh Kesari, who we announced last week. We are building a world class SAB to assist the Company’s research strategy and product development. To accomplish this purpose, the Advisory Board will review and monitor the science, processes and procedures, and infrastructure underlying the Company’s major development programs,” said Timothy Dixon, President and CEO.
“I am delighted to join TSOI in an advisory role. The convergence of the revolution in genetic analysis with the understanding of the multifaceted role of the microbiome strategically places TSOI in an exciting position. I anticipate this SAB will provide significant added value to TSOI and allow it to make significant strides in accelerating the commercialization of its current and future intellectual property,” said Dr. Lander.
Dr. Lander received a B.S. in Biochemistry and a B.A. in Chemistry from State University at Stony Brook in 1987, a Ph.D. in Biochemistry from Cornell University Graduate School of Medical Sciences in 1992 and an MBA in Finance from the New York University Stern School of Business in 2001.
About Therapeutic Solutions International, Inc.
The Company’s corporate website is www.therapeuticsolutionsint.com
. Our new products can be viewed on www.projuvenol.com
and products can be ordered at www.youcanordernow.com
These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.